Compare · FTRE vs ILMN
FTRE vs ILMN
Side-by-side comparison of Fortrea Holdings Inc. (FTRE) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FTRE and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $23.91B, about 15.3x FTRE ($1.57B).
- Over the past year, FTRE is up 201.2% and ILMN is up 86.1% - FTRE leads by 115.1 points.
- ILMN has been more active in the news (22 items in the past 4 weeks vs 6 for FTRE).
- Both have 25 recent analyst ratings on file.
- Company
- Fortrea Holdings Inc.
- Illumina Inc.
- Price
- $16.57+2.95%
- $158.13-2.55%
- Market cap
- $1.57B
- $23.91B
- 1M return
- +6.36%
- +14.02%
- 1Y return
- +201.18%
- +86.08%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2000
- News (4w)
- 6
- 22
- Recent ratings
- 25
- 25
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest FTRE
- Chief Operating Officer Morais Mark A. converted options into 11,006 shares and sold $75,374 worth of shares (4,866 units at $15.49), increasing direct ownership by 9% to 76,039 units (SEC Form 4) (tax withholding)
- Chief Financial Officer Mcconnell Jill G. converted options into 11,006 shares and sold $75,374 worth of shares (4,866 units at $15.49), increasing direct ownership by 8% to 78,416 units (SEC Form 4) (withholding obligation)
- Fortrea to Attend Jefferies Global Healthcare Conference
- Chief Accounting Officer Parks Robert sold $26,880 worth of shares (2,000 units at $13.44), decreasing direct ownership by 9% to 20,389 units (SEC Form 4)
- Director Neupert Peter M converted options into 148,536 shares, increasing direct ownership by 151% to 246,668 units (SEC Form 4)
- SEC Form 144 filed by Fortrea Holdings Inc.
- SEC Form 10-Q filed by Fortrea Holdings Inc.
- Fortrea Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Fortrea Reports First Quarter 2026 Results
- SEC Form DEFA14A filed by Fortrea Holdings Inc.
Latest ILMN
- Illumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solution
- SVP, Chief People Officer Leckman Patricia sold $127,068 worth of shares (784 units at $162.08), decreasing direct ownership by 3% to 22,042 units (SEC Form 4)
- Director Meister Keith A. sold $107,042,631 worth of shares (669,596 units at $159.86) (SEC Form 4)
- Chief Legal Officer Davies Scott M sold $98,400 worth of shares (615 units at $160.00), decreasing direct ownership by 3% to 21,568 units (SEC Form 4)
- VP, Chief Accounting Officer Ericksen Scott D sold $305,150 worth of shares (2,000 units at $152.57), decreasing direct ownership by 12% to 14,446 units (SEC Form 4)
- Integrated DNA Technologies Announces End-to-End Oncology Research Workflows Optimized on Illumina Software for Faster Insights
- Amendment: SEC Form 4 filed by Director Meister Keith A.
- Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research
- Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research
- Illumina Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits